Hematinics

All Drugs and Chemicals

Liver Extracts

People who received routine physical examination including blood test, and after 3 year follow-up, have not been diagnosed as any kind of malignant tumor.

People who were diagnosed as one of the following malignant disease: breast cancer, lung cancer, gastric cancer， esophageal cancer，colorectal cancer，nasopharyngeal cancer，liver cancer and cervical cancer

Ruihua Xu, Doctor

In prospective part of study, the investigators have found that the parameters of routine blood tests can differentiate varieties of malignancy from healthy people.

The investigators enrolled healthy subjects and patients with malignancy that aged from 18 to 85，and collected their clinical data and blood tests result to build the model.And retrospectlly enroll healthy subjects and patients to test the model.

Prospective Screening Programme for Malignant Tumors

A Large-scale, Prospective Screening Programme for Malignant Tumors Using Routine Blood Tests Parameters

The proportion of persons with disease who have a positive test (positive test results among persons with disease)

The proportion of persons without disease who have a negative test (negative test results among persons without disease)

First Affiliated Hospital, Sun Yat-Sen University

Sixth Affiliated Hospital, Sun Yat-sen University

Sun Yat-sen University

President

Symptoms and General Pathology

Wounds and Injuries

All Conditions

Blood and Lymph Conditions

Rare Diseases

Hyperthermia

Neutropenia

Fever

Febrile Neutropenia

Agranulocytosis

Leukopenia

Cytopenia

Hematologic Diseases

Leukocyte Disorders

Granulocytopenia

Lenograstim

Defined as risk of severe neutropenia \>20% or risk of neutropenic infective complications \>10%, with severe neutropenia defined as absolute neutrophil count \<1.0 x10\^9/L.

The intervention is home finger-prick capillary blood count monitoring (up to daily).

Defined as high number of cases of neutropenia, but risk of severe neutropenia \<5%.

The intervention is home finger-prick capillary blood count monitoring (up to daily).

Patients on primary prophylactic granulocyte colony stimulating factor (GCSF).

The intervention is home finger-prick capillary blood count monitoring (up to daily).

A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.

Home finger-prick capillary blood count monitoring

Geoff Hall, FRCP, PhD

Elaine Dunwoodie, MB ChB

The purpose of this trial is to observe the changes in white cell counts in patients with cancer during chemotherapy and to determine if changes in the white cell count in the early days during chemotherapy can be used as a predictor of severe neutropenia and its complications.

Neutropenia is a low count of the type of white blood cells that fight bacterial infection. It is a common toxicity of chemotherapy given for cancer. When complicated by infection, it can necessitate urgent admission to hospital, and can be life-threatening. Recovery of neutrophils is necessary prior to delivery of further chemotherapy. The information available on the changes of neutrophils during chemotherapy is limited by the frequency of blood tests which have historically required a venous blood sample and hence are burdensome to the patient.

There are point-of-care medical devices which measure the white blood cell count from a capillary finger-prick sample, and can be used in the patient's home. The investigators aim to use such a device in this trial to; (i) observe the changes in white cell counts following chemotherapy delivery, (ii) determine if changes in the white cell count in the early days during chemotherapy can be used as a predictor of severe neutropenia and its complications.

This trial forms part of a larger project in which the investigators are exploring the role of home blood count monitoring in the management of severe neutropenia and its complications, and exploring the potential for home blood count monitoring to be used to optimise the dose intensity and density of chemotherapy.

This is a non-randomised trial in adults with solid tumours, recruiting from Leeds Teaching Hospitals NHS Trust only. Consenting participants are required to have regular finger-prick blood tests up to a maximum frequency of daily for the duration of the first cycle of chemotherapy, most commonly 3 weeks. A nurse will visit the participant at home and use the Hemocue® WBC DIFF to perform the test.

This trial is funded by a Technology Strategy Board (Innovate UK) Small Business Research Initiative grant.

Profiling Neutrophil Counts in Patients on Chemotherapy

Profiling Neutrophil Counts in Patients With Cancer During Cycle One of Chemotherapy

Critical time points for measuring neutrophil counts will be determined dependent upon patterns of neutrophil changes observed and the gradient of neutrophil changes will be categorized according to limits determined by logistic regression modelling and hazard ratio calculations.

The trial data will inform the decision ratios in the Markov model. Aggregated costs associated with each pathway have been calculated using Health Resource grouper software for finished consultant episodes from an audit of patients receiving chemotherapy over a 10 year period at a large Cancer Centre in the United Kingdom. The real numbers and potential numbers in each pathway will be compared to estimate the cost implications.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Prospective Screening Programme for Malignant Tumors	NCT04230200	Hematologic Tes... Malignant Tumor		18 Years - 75 Years	Sun Yat-sen University
Profiling Neutrophil Counts in Patients on Chemotherapy	NCT02806557	Neoplasms Neutropenia Febrile Neutrop...	Home finger-pri...	18 Years -	University of Leeds
Profiling Neutrophil Counts in Patients on Chemotherapy	NCT02806557	Neoplasms Neutropenia Febrile Neutrop...	Home finger-pri...	18 Years -	University of Leeds

Spots Global Cancer Trial Database for hematologic tests